INDIANAPOLIS, 28 October 2026 — Eli Lilly's experimental next-generation diabetes drug retatrutide outperformed Novo Nordisk's Ozempic on blood sugar control and delivered more than double the weight loss in a late-stage head-to-head trial of adults with type 2 diabetes, the US drugmaker announced on Wednesday, in results that could reshape the race for the next generation of obesity and diabetes treatments if the drug wins regulatory approval.
Illustration: A once-weekly diabetes injection pen on a doctor's desk beside a blood sugar monitor and health charts.
What Happened
Eli Lilly said on Wednesday, 28 October 2026, that its drug retatrutide beat Ozempic in a late-stage trial in adults with type 2 diabetes, according to Reuters. The head-to-head study compared two doses of retatrutide — 9 milligrams and 12 milligrams — against a 2 milligram dose of Ozempic, Novo Nordisk's diabetes drug. Lilly said it used Ozempic 2 mg as the comparator because it is the highest approved dose available.
The numbers were striking. Both doses of retatrutide lowered A1C — a measure of average blood sugar over time — by 2.2 per cent on average, compared with 1.8 per cent for Ozempic, after 80 weeks of treatment. On weight, the gap was wider still: patients taking retatrutide lost an average of 44.3 pounds on the 9 mg dose and 47.4 pounds on the 12 mg dose, against 20.9 pounds for those on Ozempic. In other words, retatrutide delivered more than twice the weight loss of its rival in the same trial.
Lilly also reported that retatrutide delivered greater improvements than Ozempic across certain cardiovascular risk factors, although the company did not detail every measure in its announcement. The trial results were reported by the company rather than published in a peer-reviewed journal, and retatrutide remains experimental — it has not been approved by regulators, and the company itself framed the findings in conditional terms.
"Based on these results and those from across our Phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions," said Kenneth Custer, president of Lilly Cardiometabolic Health.
Background
Retatrutide belongs to a new wave of metabolic medicines that go beyond the current generation of weight-loss and diabetes drugs. It is given once a week and activates three hormone receptors at once — GLP-1, GIP and glucagon — earning it the nickname "triple-G" among researchers and investors. By contrast, Ozempic targets a single receptor, GLP-1, and the current market leaders in the class typically combine one or two hormonal pathways.
The idea behind the triple approach is that each hormone contributes something different. According to Lilly and researchers in the field, combining appetite suppression, blood sugar control and increased calorie burning should produce greater weight loss than earlier generations of drugs, which mainly work by reducing appetite and slowing digestion. The new trial is the first head-to-head evidence in diabetes patients that the theory translates into a measurable advantage over an established rival.
The result lands in the middle of an intense commercial contest. Lilly and Novo Nordisk dominate the global market for diabetes and obesity medicines, and both are racing to bring more powerful successors to their current blockbusters to market. Novo Nordisk's Ozempic and its obesity sibling Wegovy transformed the treatment of diabetes and obesity; Lilly's own Mounjaro and Zepbound, which combine GLP-1 and GIP, have become formidable competitors. Retatrutide would be Lilly's next step beyond that dual approach — and for patients, the stakes are clinical as well as commercial, since excess weight worsens blood sugar control, blood pressure and heart risk.
Illustration: A person standing on a bathroom scale in a bright modern home, a hopeful image of a weight-management journey.
Why It Matters
The trial matters for three reasons. First, it is a head-to-head comparison, not a contest against a placebo. Beating an approved, widely used drug by a clear margin on both blood sugar and weight is a stronger signal than beating no treatment at all, and it is the kind of evidence regulators, doctors and insurers weigh most heavily.
Second, the size of the weight-loss gap is hard to ignore. Losing roughly 44 to 47 pounds, against about 21 pounds on Ozempic, moves retatrutide into territory previously associated mainly with bariatric surgery rather than medication. For people with type 2 diabetes, weight loss of that scale can improve blood sugar control and lower cardiovascular risk — consistent with Lilly's report of greater improvements in certain heart-related risk factors.
Third, the result sharpens the competitive picture. If retatrutide is approved, Novo Nordisk will face a rival that outperforms its flagship diabetes drug on the two measures patients and doctors care about most — pressure that could accelerate Novo's own next-generation candidates and, over time, affect pricing and access.
There are important caveats. The results come from the company's own announcement, and the full trial data — including safety and side-effect details — will need scrutiny by regulators and independent researchers before any approval decision. How retatrutide's tolerability compares with Ozempic's in routine use is not yet clear from the headline figures, and no drug replaces the foundations of diabetes care: diet, activity and regular monitoring remain essential, and any treatment decision belongs with a clinician.
What Happens Next
Lilly is expected to submit retatrutide for regulatory review on the strength of its Phase 3 program. Regulators in the United States and Europe will examine the full dataset, including safety, before deciding whether to approve it and for which patients.
Doctors and researchers will also watch the detailed results — how many patients stayed on treatment, how side effects compared, and whether cardiovascular benefits translate into fewer heart attacks and strokes. Those details, rather than headline averages, will determine how widely the drug is adopted if it reaches the market.
For Novo Nordisk, the result adds urgency to its own pipeline, and the head-to-head defeat of Ozempic on its home ground — diabetes — will be read across the industry as a changing of the guard in the making. For patients, the practical effect is further away: even on an optimistic timetable, approval, manufacturing scale-up and insurer coverage take time. But the direction of travel is clear — diabetes and obesity medicines are getting more powerful, and the contest between the two giants is only intensifying.
Note: This article reports general health news and is not medical advice. Anyone considering a diabetes or weight-management treatment should discuss the options, benefits and risks with their own doctor.
Illustration: Scientists working in a bright pharmaceutical research laboratory on the next generation of metabolic medicines.
Sponsored: explore today's featured sponsored offers
FAQ
What is retatrutide?
Retatrutide is Eli Lilly's experimental once-weekly drug for type 2 diabetes and obesity. It activates three hormone receptors — GLP-1, GIP and glucagon — which has earned it the nickname "triple-G". It is not yet approved by regulators.
How did retatrutide compare with Ozempic in the trial?
In a late-stage head-to-head trial over 80 weeks, both retatrutide doses lowered A1C by an average of 2.2 per cent, against 1.8 per cent for Ozempic 2 mg. Weight loss averaged 44.3 pounds on the 9 mg dose and 47.4 pounds on the 12 mg dose, compared with 20.9 pounds on Ozempic — more than double.
Why is the trial being called head-to-head?
Because retatrutide was tested directly against an approved drug, Ozempic, rather than against a placebo. Head-to-head results are considered stronger evidence, since they show whether a new drug actually beats an existing treatment.
What does "triple-G" mean?
It refers to the three hormone pathways the drug activates: GLP-1 and GIP, which help control appetite and blood sugar, and glucagon, which is associated with increased calorie burning. The combination is intended to produce greater weight loss than single- or dual-pathway drugs.
When could retatrutide become available?
That depends on regulatory review. Lilly must submit its full Phase 3 data to regulators, who will assess safety and effectiveness before any approval. No approval date has been announced, and availability would also depend on manufacturing and insurance coverage.
Sources
- Reuters, "Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial", 28 October 2026
- Eli Lilly and Company, trial results announcement, 28 October 2026 (as reported by Reuters)
Comments
Post a Comment